As of October 2016 the three Phase III clinical trials of<unk>  used to obtain approval had not been published. Based on published data from clinical trials at that time, the most common adverse events were infusion reactions including itchy skin, rash, hives, flushing, throat and mouth irritation, fever, fatigue, nausea, rapid heart beating, headache, and dizziness. One person died from a systemic inflammatory response syndrome and in another trial, rates of cancer were three times higher (2.3% vs. 0.8%) in people taking the drug than people taking placebo. Clinical trials in rheumatoid arthritis and lupus were halted because rates of serious infections were too high; these results were not seen in published trials in people with MS, and the differences may be due to the differences in the bodies of people with the different diseases, as well as other drugs they were taking. There is an increased risk of infections of all kinds, including respiratory infections, in people taking immunosuppressive drugs like<unk> . In clinical trials submitted to the FDA, more people taking<unk>  got infections than people taking Interferon beta-1a did, including upper and lower respiratory infections, herpes, and hepatitis B reactivation. The risk of progressive multifocal leukoencephalopathy, a disease caused by viral infection of the brain, is also increased. An increased risk of malignancy with<unk>  may exist. In controlled trials, malignancies, including breast cancer, occurred more frequently in<unk> -treated patients. Breast cancer occurred in 6 of 781 females treated with<unk>  for MS in clinical trials. None of 668 females treated in Rebif (interferon beta-1a) or placebo arms of the clinical trials developed breast cancer. Patients should follow standard breast cancer screening guidelines.
Ocrelizumab
Risankizumab
Ibalizumab
Theralizumab
Brolucizumab
Atezolizumab
Inebilizumab
Etaracizumab